Evolus Turns Profitable, But Shares Keep Falling

Evolus (EOLS) reported fiscal 2025 Q4 earnings on March 3, 2026, marking a return to profitability after a prior-year loss. The company beat GAAP EPS expectations by $0.05 but missed revenue forecasts by $0.38 million. Guidance for 2026 revenue ($327M–$337M) aligns with its 10%–13% growth target, though the Zacks Rank #4 (Sell) suggests near-term underperformance risks.

Revenue

The total revenue of Evolus increased by 14.4% to $90.30 million in 2025 Q4, up from $78.95 million in 2024 Q4 .

Earnings/Net Income

Evolus returned to profitability with EPS of $0.00 in 2025 Q4, reversing from a loss of $0.11 per share in 2024 Q4 (101.9% positive change). Meanwhile, the company achieved a remarkable turnaround with net income of $130000 in 2025 Q4, representing a 101.9% positive swing from the net loss of $-6.79 million in 2024 Q4. This marks a significant improvement in financial health despite ongoing operational challenges.

Price Action

The stock price of Evolus has edged down 1.67% during the latest trading day, has dropped 3.95% during the most recent full trading week, and has tumbled 11.37% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Evolus (EOLS) shares after a revenue drop quarter-over-quarter on the financial report release date and holding for 30 days resulted in a significant underperformance. The strategy's CAGR was -19.88%, with a total return of -58.51% outperforming the benchmark return of 56.86% only by a margin of -115.37%. The strategy's maximum drawdown was 74.96%, indicating a high-risk profile with substantial losses during market downturns.

CEO Commentary

David Moatazedi, President and Chief Executive Officer, highlighted Evolus’ 12% full-year 2025 revenue growth, driven by Jeuveau’s 14% Q4 acceleration and Evolysse’s market adoption. He emphasized the company’s “beauty-first” strategy, leveraging cash-pay partnerships and co-branded media investments via the Evolus program to drive share gains. Strategic priorities include expanding Evolysse through sampling initiatives, enhancing medical education (e.g., 2-day training events), and international growth, with France and Germany as key markets. Moatazedi expressed optimism about 2026, noting structural expense reductions enabling low to mid-single-digit adjusted EBITDA margins and 13%-15% margins by 2028. He underscored confidence in Jeuveau’s differentiation and Evolysse’s Cold-X technology, which supports natural aesthetics and patient retention via the Evolus Rewards program.

Guidance

Evolus guided to 2026 total net revenue of $327 million-$337 million (10%-13% growth), with Evolysse and Jeuveau contributing 10%-12% of revenue. Adjusted gross margin is projected at 65.5%-67%, non-GAAP operating expenses at $210 million-$216 million (0%-3% growth), and low to mid-single-digit adjusted EBITDA margins. The company targets $450 million-$500 million revenue and 13%-15% adjusted EBITDA margins by 2028, supported by U.S. Jeuveau share growth to mid-teens, Evolysse share to high single digits, and international revenue exceeding 15% of total sales.

Additional News

Recent developments highlight Evolus’ strategic focus amid a challenging market. The company’s Zacks Industry Rank places it in the bottom 41% of 250+ industries, underscoring broader sector pressures. Analysts note a "Sell" rating due to unfavorable earnings estimate revisions, with consensus projecting a $0.11 loss per share for the coming quarter. Share price underperformance, down 35.5% year-to-date versus the S&P 500’s 0.5% gain, reflects investor skepticism. Management’s emphasis on cost reductions and international expansion aims to counter these headwinds, though execution risks remain.